Nanoform appoints Miguel Calado as Chairman of the Board
Nanoform has appointed Miguel Calado as Chairman of the Board.
A message from Nanoform regarding COVID-19
The COVID-19 pandemic is evolving rapidly, and we would like to assure our customers, partners, and suppliers that we are diligently monitoring the situation and follow the most up-to-date World Health Organization, EU, and local government guidelines.
Nanoform and Orion collaborate on next-generation drug development
Nanoform and Orion Corporation, a Finnish pharmaceutical company, today announced a collaboration to apply Nanoform’s award-winning CESS® technology to new chemical entities.
Nanoform establishes US subsidiary
Nanoform has established Nanoform USA Inc., a wholly owned subsidiary in the US.
Nanoform files for GMP certification
Nanoform has filed for GMP status with the Finnish Medicines Agency, FIMEA. The drug substance application for GMP clinical manufacture certification exemplifies its progress and growth in the last 12 months.
Nanoform wins the CPhI Excellence in Pharma Award for Formulation
Nanoform, an innovative medicine enabling nanotechnology company, has won the Excellence in Pharma Award for Formulation at the prestigious CPhI Pharma Awards.
Nanoform nominated for CPhI Award!
We are delighted to have been shortlisted as a finalist for the CPhI Award in the Excellence in Pharma: Formulation category.
Nanoform and AstraZeneca Initiate Technology Evaluation
Nanoform is delighted to announce the initiation of a technology evaluation of Nanoform’s Proprietary CESS Technology across a range of AstraZeneca’s proprietary pharmaceutical products.